Between 2007 and 2011, clinical trials taking place in the European Union fell by 25%. Why? In a recent post by Glenis Willmott is a member of the European Parliament (MEP) for the East Midlands region at NHS Voices, she cites high costs of staffing fees and insurance along with delays in authorization. This has caused may sponsor companies of clinical trials to leave the region and take place elsewhere.
However, with the effort to push new legislation through the European parliament, her goal is to make changes that will bring clinical trials back to the region. Her goal is to make changes to bring clinical trials back to the UK and European region by creating a system that has fewer administrative setbacks and allows the time between paperwork submission from a patient and treatment to shrink. They will also work to bring down the constraints each individual country poses with their regulation through a single EU portal to accept trial applications. Willmont is also striving to bring more transparency to clinical trials by way of sharing critical information throughout the process such as why clinical trials stop.
This year, Partnerships in Clinical Trials will take place April 22-24, 2013 in Orlando, Florida. We'll be addressing the evolving landscape of clinical trials the the regulation restrictions faced by many sponsor companies around the world. For more information on the event, sign up to receive updates about the 2013 program. If you'd like to join us, register today and save 15% off the standard rate!
What will creating an environment where it's easier to conduct clinical trials across regions in Europe do for the clinical trial industry?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to email@example.com.